hVIVO (LON:HVO) Shares Up 7.4% – Still a Buy?

hVIVO plc (LON:HVO) shot up 7.4% on Tuesday . The stock traded as high as GBX 6.50 and last traded at GBX 6.50. 15,129,095 shares changed hands during mid-day trading, an increase of 339% from the average session volume of 3,444,448 shares. The stock had previously closed at GBX 6.05.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HVO. Peel Hunt reissued an “add” rating and issued a GBX 10 price objective on shares of hVIVO in a research note on Thursday, November 20th. Shore Capital Group reiterated a “buy” rating and set a GBX 25 target price on shares of hVIVO in a report on Thursday, January 29th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, hVIVO presently has a consensus rating of “Buy” and a consensus target price of GBX 17.50.

hVIVO Stock Up 17.4%

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm’s fifty day simple moving average is GBX 6.03 and its 200 day simple moving average is GBX 7.46. The company has a market cap of £48.79 million, a price-to-earnings ratio of 9.22 and a beta of 0.97.

Insider Activity

In other hVIVO news, insider Stephen Pinkerton purchased 520,000 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average cost of GBX 6 per share, with a total value of £31,200. Also, insider Yamin Mo’ Khan purchased 3,310,405 shares of the company’s stock in a transaction on Monday, December 15th. The stock was bought at an average price of GBX 6 per share, for a total transaction of £198,624.30. Corporate insiders own 5.25% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.